Monday, August 01, 2022 8:01:15 AM
7:52 pm ET July 27, 2022 (BusinessWire) Print
MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the pricing of its initial public offering of 2,000,000 shares of the Company's common stock at a public offering price of $5.00 per share for aggregate gross proceeds of $10,000,000 prior to deducting underwriting discounts, commissions, and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 300,000 shares of common stock at the public offering price, less discounts and commissions, to cover over-allotments.
The shares of common stock are expected to begin trading on the NYSE American under the ticker symbol "MAIA" on July 28, 2022. The offering is expected to close on August 1, 2022, subject to the satisfaction of customary closing conditions.
The Company intends to use the net proceeds from the initial public offering to fund the first part of the Phase 2 trials of the Company's product candidate THIO, pre-clinical development of second-generation of telomere targeting compounds and other research and development activities, as well as for working capital and other general corporate purposes.
ThinkEquity is acting as sole book-running manager for the offering.
The registration statement on Form S-1 (file No. 333-264225) relating to the shares being sold in this offering has been filed with the U.S. Securities and Exchange Commission (the "SEC") and became effective on July 27, 2022. A final prospectus related to the proposed offering will be filed and made available on the SEC's website at https://www.sec.gov/. The offering is being made only by means of a prospectus. Electronic copies of the final prospectus may be obtained, when available, from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004, by telephone at (877) 436-3673 and by email at prospectus@think-equity.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About MAIA Biotechnology, Inc.
MAIA is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company's lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of patients with telomerase-positive cancers. For more information, please visit www.maiabiotech.com.
Forward Looking Statements
This press release includes forward-looking statements including, but not limited to, statements related to the closing of the offering and the expected use of proceeds, development of drug candidates, our operations and business strategy, our expected financial results, and corporate updates. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties, including, among others, those related to our ability to obtain additional capital on favorable terms to us, or at all, including, without limitation, to fund our current and future preclinical studies and clinical trials and the success, timing and cost of our drug development program and our ongoing or future preclinical studies and clinical trials, including, without limitation, the possibility of unfavorable new clinical and preclinical data and additional analyses of existing data, that the risks that prior clinical and preclinical results may not be replicated, and risks associated with the current coronavirus pandemic. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220727006179/en/
SOURCE: MAIA Biotechnology, Inc.
Investor Inquiries
ICR Westwicke
Stephanie Carrington
Stephanie.carrington@westwicke.com
646-277-1282
New York Yankees and Duke Basketball
Recent MAIA News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/10/2024 10:15:29 AM
- MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer • Business Wire • 09/10/2024 10:00:00 AM
- MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference • Business Wire • 09/04/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 08:06:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/23/2024 09:05:10 PM
- MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent • Business Wire • 07/23/2024 08:11:00 AM
- MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA’s Approval of a Telomerase Inhibitor Agent Therapy • Business Wire • 06/07/2024 04:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 06:57:40 PM
- MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent • Business Wire • 06/06/2024 02:07:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 08:06:02 PM
- MAIA Biotechnology Reveals New Clinical Data Showing THIO’s Strong Efficacy in Non-Small Cell Lung Cancer • Business Wire • 06/04/2024 12:41:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 08:05:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 08:05:58 PM
- MAIA Biotechnology to Present at the BIO International Convention 2024 • Business Wire • 05/17/2024 12:37:00 PM
- MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting • Business Wire • 05/16/2024 12:37:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:07:15 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/15/2024 08:05:52 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:11:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 09:21:03 PM
- MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement • Business Wire • 04/30/2024 12:08:00 PM
- MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement • Business Wire • 04/29/2024 12:08:00 PM
- MAIA Biotechnology Announces $1.00 Million Private Placement • Business Wire • 04/23/2024 12:51:00 PM
- MAIA Biotechnology to Present at Two Investor Conferences in April 2024 • Business Wire • 04/05/2024 12:01:00 PM
- MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero • Business Wire • 03/28/2024 07:00:00 PM
- MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement • Business Wire • 03/26/2024 07:00:00 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM